HIV-1 coreceptor, or a low or attenuated virus inoculum. Thirty-seven HIV-1-uninfected persons engaging in repeated high-risk sexual activity with an HIV-1-infected partner were prospectively studied to determine the contribution of these factors in protecting against HIV-1 transmission. More than one-third (13/36) demonstrated HIV-1-specific cytotoxicity, and this activity significantly correlated with the wild type CCR5 genotype ( ). Only 1 subject P ϭ .03 (3%) demonstrated the homozygous CCR5 32-bp deletion (D32/D32). Median plasma HIV-1 RNA levels from 18 HIV-1-infected sex partners were not statistically different from those of matched infected control patients. These results indicate that inheritance of the D32 CCR5 mutation does not account for the majority of persistently HIV-1-resistant cases, and the presence of cellular immunity in these persons suggests either undetected infection or protective immunity.
occupational HIV-1 exposures [8, 9] . In addition, exposure to a low inoculum or virions with altered infectivity may be important in limiting transmission. In such cases, the virus exposure may be insufficient to initiate infection or may prime an immune response that confers protection or restricts high levels of replication.
Recent evidence indicates that in at least some exposed but uninfected persons, the homozygous inheritance of a defective HIV-1 coreceptor, CCR5, may explain their "resistance" to HIV infection [10] [11] [12] [13] . A 32-bp deletion renders the coreceptor nonfunctional, which confers resistance of CD4 cells to infection with macrophage-tropic viruses. However, inheritance of the homozygous D32-CCR5 deletion (D32/D32) does not account for all cases of apparent resistance to HIV. For example, this defect is either absent or extremely rare in persons of African heritage [11, 14] and thus is unlikely to play a role in the African cohorts who demonstrate long-standing persistent seronegativity despite repeated HIV-1 exposure [4, 7] . In addition, recent reports [15] [16] [17] indicate that HIV-1 infection can occur, albeit uncommonly, in persons who have the homozygous defect, which implies that other mechanisms of protection must also be involved.
Among 37 HIV-1-uninfected persons who fit standardized criteria for repeated high-risk sexual exposure to HIV-1, we examined, over the course of ∼2 years, the contribution of inherited versus acquired resistance to HIV-1 infection. We also evaluated 18 of the subjects' HIV-1-infected partners to obtain information about their clinical disease and virus load.
Materials and Methods
Study group. Healthy HIV-1-seronegative persons у18 years old with high-risk exposure to HIV-1 through sexual activity were recruited within metropolitan Seattle through local advertisements, their infected partners, community physicians, sexually transmitted disease clinic providers, the Seattle AIDS Prevention Project, and the University of Washington AIDS Vaccine Evaluation Unit. Preestablished enrollment criteria included unprotected sexual intercourse (anal and/or vaginal intercourse without condoms) with a known HIV-1-infected person more than five times in the previous 6 months or an average of two times weekly over 4 months within 2 years of enrollment. Prior receipt of an HIV-1 vaccine and pregnancy were exclusion criteria. A medical history, physical examination, complete blood cell count, T cell subset analysis, and HIV-1 testing were done at the screening visit to confirm eligibility. HIV-1 infection was excluded by the following tests done on the screening visit and study day 0: HIV-1/2 ELISA and Western blot [18] , HIV-1 plasma RNA reverse transcriptase (RT)-polymerase chain reaction (PCR) [19] , and peripheral blood mononuclear cell (PBMC) DNA PCR [20] . HIV-1 risk reduction counseling was done at each visit. The volunteers donated blood and, when possible, semen for virologic and immunologic studies. They also completed a questionnaire concerning risk behavior, which was administered by the clinician at each follow-up visit scheduled every 1-3 months for up to 24 months.
We also sought participation by any HIV-1-seropositive sex partner of each high-risk subject. The infected volunteers reported the date of their first known positive HIV-1 test, their clinical disease course, and antiretroviral drug history. HIV-1 infection was confirmed in the repeated sexual contacts on the first visit by HIV-1 ELISA and Western blot. Flow cytometry was used to enumerate T cell subsets. HIV-1 RNA copy number was measured by RT-PCR (Amplicor HIV Monitor; Roche Molecular Systems, Branchburg, NJ) in plasma and seminal plasma. Seminal plasma specimens were pretreated with silica gel as previously described [21] . Virus isolation from PBMC coculture was measured by p24 production in the supernatant by quantitative microculture with 10 5 autologous PBMC or qualitative microculture with 10 6 autologous PBMC. Uninfected volunteers at low risk for HIV-1 recruited from the Seattle area served as controls for the cellular immunity and in vitro HIV-1 infectivity studies. For comparisons of virus load between the HIV-1-infected partners, controls were derived from study participants at the University of Washington AIDS Clinical Trials Unit or Center for AIDS Research Primary Infection Clinic. The control cases were matched by antiretroviral treatment, peripheral blood CD4 cell count ‫001ע(‬ cells/mL), and time of clinic evaluation ‫6ע(‬ months).
HIV-1-specific precursor cytotoxic T lymphocyte (pCTL) frequencies. pCTL frequencies were measured in a limiting dilution assay as previously described [22] . In brief, autologous monocytes were infected with recombinant vaccinia virus (rVV) encoding HIV-1 LAI Env, Gag, and Pol (provided by D. Panacali, Therion, Cambridge, MA), gamma-irradiated (3000 rad), and used as HIV-specific stimulator cells [23] . Serial dilutions of fresh autologous PBMC were plated in 96-well round-bottomed microtiter plates in 24-well replicates to generate effector cells. Stimulator cells (3000 cells), irradiated autologous PBMC (50,000 cells), and 10 U of human recombinant interleukin-2 (Chiron, Emeryville, CA) were added to each well and cultured under conditions previously described [22] .
Autologous Epstein-Barr virus-transformed B lymphoblastoid cell lines, established from PBMC of each donor, were infected on day 9 with rVV and labeled with 100 mCi of [ 51 Cr]Na 2 CrO 4 (NEN Products, Boston) overnight. On day 10, the effector cell suspension from each well was equally divided into 4 wells and tested for lysis of radiolabeled autologous targets previously infected with 3 5 ϫ 10 rVV, containing either HIV-1 MN env gp160 (1174) or HIV-1 LAI gag/ pol (1206) (provided by J. Tartaglia, Virogenetics, Troy, NY) or HIV-1 LAI gag (vDK-1), HIV-1 LAI pol (vRT), or lacZ control (vSC8) (provided by the National Institutes of Health AIDS Reagents Repository). Sixteen wells of each of the four infected targets were incubated with media alone and 16 with 5% Triton X-100 to determine spontaneous and maximum chromium release, respectively. After a 4-h incubation at 37ЊC, culture supernatants were harvested, and 51 Cr release was measured (Topcount radioisotope counter; Packard Instrument, Rockville, MD). The spontaneous release was always !20% of the maximum release, and the SD of replicate wells for the spontaneous release was !15%. Cells from wells associated with lysis exceeding the mean spontaneous release by 3 SD were considered positive. The frequency of antigen-specific CTL precursors was estimated from the initial responder cell number at which 37% of the wells were negative for cytotoxicity on the basis of the single-hit Poisson model. The frequencies were expressed as pCTL/10 6 PBMC, and confidence intervals were determined by software provided by S. Kalams (Harvard University, Boston). We defined a positive HIV-specific CTL response as occurring when the frequencies of pCTL recognizing the HIV-specific target were у10 pCTL/10 6 PBMC and when the confidence intervals for HIV-specific pCTL frequencies did not overlap those for the control target.
Lymphoproliferative responses. PBMC were incubated in quadruplicate cultures at 10 5 cells/well in 96-well round-bottomed plates for 6 days in the presence of recombinant HIV-1 antigens (5 mg/ mL). These included HIV-1 SF-2 rgp120 (Chiron), HIV-1 LAI p24 (MicroGeneSys, Meriden, CT), and HIV-1 LAI gp160 (MicroGeneSys) and their corresponding control proteins. In addition, cells were also stimulated with Candida (20 mg/mL; Connaught Laboratories, Toronto) and tetanus (50 U/mL; Connaught Laboratories) recall antigens. Wells were pulsed with 2. 30 s, and 72ЊC for 30 s, and the amplified products were separated on a 2% agarose gel by electrophoresis.
To assess whether each CCR5 gene was functional, we amplified the coding region of CCR5 by PCR from genomic DNA. Amplified PCR fragments were cloned into pCR3.1 downstream from a cytomegalovirus promoter (Invitrogen, Carlsbad, CA). CCR5 constructs were transiently transfected into MAGI cells expressing the CD4 gene, which also contains an integrated copy of the b-galactosidase gene under the control of the HIV-1 long terminal repeat [24] . Transfected cells were then scored for infectivity by a macrophage-tropic strain, YU2, by counting b-galactosidase-positive cells by use of the MAGI cell assay as previously described [24] .
In vitro HIV-1 infectivity studies. PBMC were stimulated with phytohemagglutinin (2 mg/mL; Sigma, St. Louis) for 72 h at 37ЊC. CD8 lymphocytes were depleted from the nonadherent cell fraction by use of magnetic microbeads containing anti-CD8 monoclonal antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD4-enriched cells (195% by flow cytometry) were added to a 96-well plate in duplicate at cells/well and infected with 600 5 2 ϫ 10 TCID 50 of either HIV-1 LAI , HIV-1 SF-2 , or a primary patient isolate HIV-1 DK1017 for 4 h at 37ЊC. The cells were washed to remove residual virus in the supernatant and cultured with RPMI containing 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA), and medium was replaced every 4 days. Cell culture supernatants were harvested at days 4, 7, and 14 after infection and analyzed for RT activity [25] and p24 production by use of commercial kits (Abbott Laboratories, Abbott Park, IL).
HIV strains isolated from the seropositive partners were characterized for coreceptor usage by infection of indicator cells that express only CCR5 or CXCR4 as HIV coreceptors [26] . In brief, these indicator cells, derived from U373 cells expressing CD4 and an integrated HIV-1 long terminal repeat driving expression of bgalactosidase [27] , were infected with retrovirus vectors that expressed either CXCR4 or CCR5. Coreceptor usage was defined by the ability to induce b-galactosidase activity 2 days after infection of the indicator cells. The efficiency of infection is quantitated as the number of blue cells (indicating cells that express b-galactosidase) per milliliter of virus inoculum.
Statistical methods. The CCR5 genotype frequencies among the study subjects were compared with published frequencies among American and Western European Caucasians by use of the x 2 test. The 2 non-Caucasian subjects in the high-risk group were excluded from this analysis. Fisher's exact test and odds ratios with 95% confidence intervals were calculated to assess the correlation between the presence of a particular CCR5 genotype and HIV-1 cellular immunity. Susceptibility to HIV-1 infection in vitro was compared between the high-risk uninfected subjects and low-risk uninfected controls by the Wilcoxon rank sum test. A t test on the log-transformed HIV-1 plasma RNA values was done to compare the virus load of the partners of high-risk subjects with the virus load of HIV-1-infected controls.
Results
The first 41 volunteers meeting the sexual risk criteria were screened for HIV-1 infection. Two had unsuspected infection diagnosed by HIV-1 ELISA and Western blot and 2 were lost to follow-up soon after the study began. Among the remaining 37 study participants, the median age was 37 years, most were male (86%) and Caucasian (94%), and the activity most frequently (78%) associated with repeated exposure to a known HIV-1-infected partner was unprotected anal receptive or insertive intercourse between men (table 1) . Thirty-three reported high-risk unprotected sexual activity with a known HIV-1-infected partner six or more times in the previous 6 months, and 4 engaged in these activities an average of two times weekly over у4 months within the past 2 years (table 1) .
The study participants remained free of HIV-1 infection by serologic and DNA PCR assays done a median of six and three times, respectively, throughout the median study period of 23 months (range, 15-30 months). Additionally, HIV-1 RNA was not detected in seminal plasma from any of the 27 male subjects tested up to ∼1 year of follow-up. When questioned during the first year of study about risk behavior over 2-to 3-month intervals, the majority continued to report unprotected sexual activity with a known HIV-1-infected partner (table 1) . More than one-fourth of the subjects also had unprotected sexual contacts with other partners of unknown HIV-1 serostatus (ta- 
4 (2-6) ble 1). Thus, despite persistent high-risk sexual behavior in most subjects, no new acquisitions of HIV-1 infections occurred among the 37 volunteers after ∼2 years of study.
HIV-1-specific CTL activities. To determine whether repeated sexual exposure to HIV-1 induces a memory CTL response, we performed pCTL frequency analysis on PBMC from 36 of the 37 subjects a median of three times over the course of follow-up. One subject (subject 32) was lost to follow-up before initiation of the CTL studies. HIV-1-specific cytolytic activity was detected in PBMC in 13 (36%) of the 36 subjects tested (table 2). The pCTL frequencies ranged from 12 to 239/ 10 6 PBMC for HIV-1 Env, 12 to 1361/10 6 PBMC for HIV-1 Gag, and 11 to 188/10 6 PBMC for HIV-1 Pol. Although the HIV-specific pCTL frequencies were low in some of the highrisk persons (e.g., subjects 13, 17, 35, 37), these were distinguishable from those in 15 HIV-1-seronegative volunteers with a history of low or no risk of HIV-1 infection (table 2) . Among these control subjects, the pCTL frequencies for the three gene products on three separate measurements were consistently !1/ 10 6 PBMC, indistinguishable from those recognizing the control targets (table 2) . Thus, detection of HIV-1-specific CTL activities was more likely to occur in the high-risk group than in the low-risk controls ( , Fisher's exact test). P ϭ .006 Among those demonstrating HIV-1-specific cytolytic responses, the specificity was more often associated with HIV-1 Env (9/13, 69%) than Gag (5/13, 38%) and Pol (4/12, 33%) (table 2). Seven of the 13 subjects recognized two or more HIV-1 gene products when expressed individually on autologous targets (table 2; figure 1 ). The 13 subjects with positive responses were tested a median of four times and exhibited positive pCTL responses during 44% of the evaluations. The highest pCTL frequencies, up to 1361 Gag-specific pCTL/10 6 PBMC, were observed in subject 1 (table 2; figure 1 ). This person had frequently positive CTL activity (figure 1), and effector responses were intermittently directed to HIV-1 Env, Gag, and Pol, as well as Nef (152 pCTL/10 6 PBMC), tested on one occasion. Similarly, in 2 volunteers (subjects 34 and 38) followed for 11 year, CTL responses were detected intermittently to Env, Gag, and/or Pol at more than one time point (figure 1). The cytotoxic activities were mediated by CD8 T cells when examined ( figure  1, visit 8 ; data not shown). Clearly, responses were low-level in some subjects and were detected at only one time point (see Figure 1 . HIV-1-specific precursor cytotoxic T lymphocyte (pCTL) frequencies in 4 HIV-1 multiply exposed seronegative volunteers (subjects 1, 34, 38, and 13) on repeated visits. Responses from limiting dilution assay are expressed as pCTL frequency (log 10 )/10 6 PBMC, based on lysis of autologous B lymphoblastoid cell lines infected with recombinant vaccinia virus expressing HIV-1 Env, Gag, or Pol minus lysis of targets infected with control Lac protein. CD8 T cells were effectors for assays shown at visit 13 in subject 1, and at visits 8 and 9 in volunteer 38, activities were mediated by CD8 T cells alone. subject 13, figure 1 ). Our findings indicate that repeated sexual contact with an HIV-1-infected partner can induce HIV-1-specific CTL in the absence of serologic and virologic evidence of infection, that these responses may be broad but intermittently detectable, and that the pCTL frequencies may reach levels similar to those attained in HIV-1 infection.
Lymphoproliferative activities. To determine whether frequent high-risk sexual contact induces T helper responses in conjunction with or in addition to CTL responses, we measured PBMC proliferative responses to HIV-1-specific antigens in the study group and compared them with responses to control antigens (Candida and tetanus antigens). Of the 4 subjects with positive responses, 3 (subjects 1, 4, and 10) exhibited proliferation to both HIV-1 Gag p24 and Env gp120 or gp160, defined by an SI у4.0 (figure 2). Moreover, 3 of the 4 subjects (subjects 1, 4, and 13) also demonstrated HIV-1-specific CTL responses. The HIV-1-specific lymphoproliferation, when positive, ranged from 1524 to 11,823 cpm ( figure 2A) and from an SI of 4 to 18 (figure 2B). Although these responses were lowlevel and occurred at only one or two time points, they were distinctly greater, particularly the p24 antigen responses, than those observed after stimulation of PBMC in low-risk seronegative volunteers, in whom median SIs of 1 were measured to HIV-1 LAI p24 (range, 1-3;
), to HIV-1 SF-2 gp120 (range, n ϭ 36 1-4;
), and HIV-1 LAI gp160 (range, 1-3; ) antigens. n ϭ 28 n ϭ 15 In comparative studies, responses to the Candida and tetanus recall antigens were detected in all exposed seronegative subjects. SIs to recall antigens varied when assessed longitudinally in each donor (figures 2C, 2D), and the level of lymphoproliferation was unrelated to the detection of lymphoproliferation to HIV-1 antigens.
CCR5 genotype and susceptibility to HIV-1 infection. To determine whether inheritance of a defective CCR5 HIV-1 coreceptor was a correlate of resistance to HIV-1 infection among these subjects, we performed DNA PCR on PBMC by use of primers that amplified the region encoding the 32-bp deletion. Of the 37 subjects, 26 (70%) exhibited the wild type (wt/wt) genotype, 10 (27%) the heterozygous (wt/D32) genotype, and 1 (3%) the homozygous (D32/D32) genotype (table 3) . Although the frequency of the heterozygous genotype was higher among our subjects than in other series, overall the frequency of these genotypes in our study population of 37 was not statistically different from published frequencies in Caucasian cohorts (83% wt/wt, 16% wt/D32, 1% D32/D32) ( ) [11, 13, 14] . There-P ϭ .07 fore, the common 32-bp deletion in CCR5 does not account for resistance to HIV-1 infection for most of this study group.
We considered the possibility that some subjects who were heterozygous for the CCR5 deletion might encode additional mutations on the nondeleted allele to explain their resistance to HIV-1. To test whether the CCR5 allele encoding the fulllength CCR5 protein in the heterozygotes was functional, we cloned the PCR-amplified CCR5 DNA into an expression vector and transfected it into CD4-positive HeLa indicator cells [24] . Two days after transfection, the cells were infected with a macrophage-tropic virus and examined for infection. In all cases, the nondeleted allele of CCR5 from the heterozygotes was able to function as a coreceptor for a macrophage-tropic strain. As controls, the deleted CCR5 alleles did not support macrophage-tropic HIV-1 infection. Therefore, additional mutations in CCR5 aside from the 32-bp deletion appeared not to account for resistance in this persistently exposed population.
To determine whether CD4 cells isolated from our uninfected high-risk subjects were susceptible to HIV-1 in vitro, we measured p24 production and RT activity after 7 and 14 days of challenge with HIV-1. For these studies, we selected 13 highrisk volunteers with representation from the three recognized genotypes as well as 7 seronegative low-risk donors with the CCR5 (wt/wt) genotype as controls. CD4 T cells from all donors could be infected by CXCR4-dependent HIV-1 SF-2 (data not shown). On challenge with the CCR5-dependent HIV- 1 DK1017 strain, all donors were susceptible to infection, with the exception of subject 7, who had the D32/D32 CCR5 genotype (data not shown). Excluding subject 7, a comparison of median RT activities of the HIV-exposed and control groups revealed no consistent differences in infectivity of CD4 cells at days 7 and 14 with HIV-1 SF-2 , HIV-1 LAI , and HIV-1 DK1017 (data not shown). Moreover, no differences in HIV-1 infectivity were noted in the wt/D32 CCR5 heterozygotes compared with the wt/wt high-risk subjects, with median RT activities after 7 days of infection of 39,500 versus 63,800 cpm/mL for HIV-1 SF-2 ( ), 57,650 versus 66,550 cpm/mL for HIV-1 LAI ( ), P ϭ .5 P ϭ .7 and 50,350 versus 22,300 cpm/mL for HIV-1 DK1017 ( ). P ϭ . 4 These results indicate that, with the exception of the D32/D32 CCR5 homozygote, CD4 cells from the repeatedly HIV-1-exposed but uninfected subjects were susceptible to HIV-1 infection with CCR5-dependent and CXCR4-dependent strains.
Comparison of cellular immunity with CCR5 genotype. HIV-1-specific CTL responses were more commonly detected in the group with wt/wt CCR5 (12/25) than in those with one or more CCR5 D32 mutations (1/11) (  ; table 3 ). More-P ϭ .03 over, an Env-specific CTL response was more likely to be detected in subjects with the wt/wt CCR5 genotype than with the wt/D32 CCR5 genotype ( ). Lymphoproliferative re-P ϭ .01 sponses to HIV-1 antigens, detected in 4 subjects, were relatively uncommon regardless of CCR5 genotype, and no positive correlations were observed (table 3) .
Clinical and virologic analysis of HIV-1-infected partners. Of the 18 HIV-1-infected sex partners of the uninfected highrisk group, 5 partners were within 1 year of diagnosis, 4 had been infected for 111 years, and only 1, the partner of subject 7 (D32/D32 CCR5 genotype), had AIDS (table 4) . The median CD4 cell count at the initial visit was 444/mL (range, 210-1015). Ten subjects reported active treatment with at least two antiretroviral agents, and 8 denied use of antiretroviral therapy (table 4) .
The median plasma HIV-1 RNA level, 11,887 copies/mL, in the sex partners was notably low, but when compared with 5939 copies/mL in the matched control group, the difference was not significant ( ). To determine whether levels of P ϭ .6 plasma HIV-1 in the infected partners were associated with CTL responses in the uninfected partners, we compared virus loads among patients whose partners had CTL (7 available of the 13 demonstrating CTL) with those of patients whose partners lacked CTL (12 available of the 23 lacking CTL). Median plasma RNA levels were not significantly different among those whose partners demonstrated CTL (3828 copies/mL) and those whose partners lacked CTL (12,604 copies/mL) ( ). In P ϭ .2 addition, virus levels in the infected patients ( ) whose n ϭ 12 partners exhibited the wt/wt CCR5 genotype were similar to levels in those ( ) whose partners had the wt/D32 genotype n ϭ 5 (6341 vs. 3828 copies/mL; ). In 4 patients, paired plasma P ϭ 1.0 and seminal plasma specimens were available, and the levels of HIV-1 RNA were similar (data not shown).
Infectious HIV-1 was isolated by PBMC coculture from 15 of the 18 partners. Of the 12 isolates tested, 11 used CCR5 as a coreceptor, as indicated by the infectivity titers in table 4, but could not use CXCR4 as a coreceptor. One isolate (partner 30) had low infectivity for cells expressing either of the coreceptors. Overall, the predominant virus strains in the partners tested were macrophage-tropic, and unusual coreceptor usage in the partner strains did not explain the lack of transmission to the high-risk seronegative sex partners.
Discussion
Our prospective study of 37 persons engaging in high-risk sexual behavior with known HIV-1-infected partners provides evidence that HIV-1-specific immunity rather than target cell resistance to infection may be the strongest correlate with protection from HIV-1. These subjects have remained uninfected for ∼2 years, as evidenced by sensitive PCR detection assays of peripheral blood and in semen (when applicable), despite persistent HIV-1 exposure in the majority of them. Admittedly, these findings do not exclude the possibility that some of the subjects have a low level of HIV-1 infection that may be detectable from another specimen source, such as lymph nodes, or by even more-sensitive PCR assays. Nonetheless, our findings suggest that nearly one-third may have combated clinical infection by mounting a cellular immune response. Clearly, other unexplored mechanisms, such as noncytolytic CD8 suppressor activities [28] , antiviral chemokines, and selective mucosal immunity [3] , also may be responsible for the suppression of HIV-1 infection. In addition, the 6 subjects whose sex partners have undetectable plasma HIV-1 RNA may not have been exposed to sufficient quantities of virus to initiate infection.
Our detection of HIV-specific CTL precursors in 13 of the 37 subjects suggests that a likely mechanism whereby persons repeatedly exposed to HIV-1 infection are capable of suppressing infection is through the induction of a specific CTL response, particularly a class I, major histocompatibility complex (MHC)-restricted CD8 response. The highest pCTL frequencies were detected to HIV-1 Gag, but responses were most often directed to HIV-1 Env, which may represent both CD8 and CD4 MHC-restricted cytolytic activities that are capable of lysing HIV-1-infected cells [23, 29] . These results provide additional support that immunodominant epitopes within HIV-1 Env may be important not only in the induction of neutralizing antibodies but also for T cell immune responses in persons with HIV-1 exposure or in early HIV-1 infection [22] . Of interest, although CTL activities were detectable more than once in 7 of 13, they were rarely persistent over the 1-2 years of study. This response pattern suggests that the ability to detect CTL may be dependent on the length of time from repeated exposure or the actual frequency of exposure relative to testing. We recognize that quantitation of HIV-specific T cells by more-recently described peptide/MHC tetramer staining and of interferon-g-producing cells may improve the estimates and clarify the regulation of these antigen-specific responses [30] . Alternatively, we cannot exclude the possibility that persons with repeatedly positive CTL responses may be infected with HIV-1 but at levels below detection by sampling from peripheral blood. If such is the case, the cytotoxic effectors may function to control viral replication and prevent overt clinical disease.
Unlike recent studies [31] indicating that a substantial proportion (19%) of similar high-risk groups bear the homozygous CCR5 deletion genotype, we found only 1 (3%) of 37 subjects with the mutant genotype. This frequency is surprisingly low and similar to the frequency of the general US Caucasian population. We provide evidence that induction of T cell immunity to HIV-1 is more likely to occur in persons with a wild type CCR5 genotype. This observation is somewhat puzzling, since those with the heterozygous genotype appear equally susceptible to infection in vitro with both CCR5-dependent and CXCR4-dependent strains. On challenge with high virus titers, the HIV-1 target cells in this group with one or more wild type CCR5 alleles are susceptible to infection with viruses commonly implicated in HIV-1 transmission. However, we cannot exclude the possibility that some of the persons with the wild type CCR5 genotype who demonstrated HIV-1 CTL responses have acquired HIV-1 infection that currently is not detectable by the sensitive methods used here.
One unique feature of this study was the opportunity to examine the HIV-1-infected sex partners. Although no specific clinical manifestation could be attributed to the lack of sexual transmission from these persons to their uninfected partners, the HIV-1 plasma levels in the infected group were lower than may have been expected before the wide use of potent antiretroviral triple-drug regimens, but not when contrasted to contemporary matched controls. Differences in plasma virus load among infected patients did not account for the ability of the uninfected partners to mount an HIV-1-specific CTL response or relate to the frequency of a specific CCR5 genotype (wt/wt or wt/D32). However, a more extensive evaluation of virus levels in the genital secretions is needed (and is in progress) to understand the relative contribution of virus inoculum and to determine whether the CTL responses detected in the high-risk seronegative subjects recognize epitopes within their partners' viral quasispecies. These results suggest that, although the highrisk partners may have reduced susceptibility to HIV-1 infection through sexual exposure, because the virus loads of their partners are low, this trend may become even more apparent as the use of potent antiretroviral combination therapy becomes more widespread. In support of this, there is evidence that HIV-1 levels in semen are similarly low to undetectable in persons receiving potent antiretroviral therapy [32] .
In conclusion, we present evidence that persons who continue to practice high-risk sexual activities with an HIV-1-infected partner are more likely to exhibit HIV-1-specific immunity than defective CCR5 HIV-1 coreceptor function. Thus, our findings support a role for cellular immunity either in directly preventing or suppressing overt infection or in denoting reduced susceptibility as a result of other undefined mechanisms. We also speculate that low levels of virus inoculum may contribute to reduction in transmission, but additional studies in transmitting and nontransmitting sex partners and more-extensive examination of virus loads in the mucosal compartments are needed to substantiate this. Further studies are needed to delineate the CTL epitope specificities and the components of the T helper responses in those with immune responses, as well as the feasibility of inducing such responses by immunization, which may lend protection to those at risk for HIV-1 infection.
